A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

Signs of inflammatory bowel disease (IBD) activity, shorter duration of IBD, and previous corticosteroid use and hospitalisation were associated with Clostridioides difficile infection in patients ...

Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

Researchers at Tufts University School of Medicine are studying C. diff at multiple levels, from how individual bacterial ...

Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position ...

Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections. Clinical trials showed Vowst significantly ...

The study of Clostridium difficile infection (CDI) continues to reveal intricate details of its pathogenesis, epidemiology and potential novel therapies. Research has elucidated how the bacterium, ...

Antibiotic use in the outpatient setting is a significant risk factor for contracting Clostridium difficile outside of a healthcare environment, according to a study published in the journal Open ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

Clostridium difficile infection rates in many healthcare facilities have not declined despite an increase in activities targeting this infection, according to a survey by the Association for ...